Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rakovina Therapeutics Inc ( (TSE:RKV) ) has shared an update.
Rakovina Therapeutics Inc. has announced the effective date for its share consolidation, set for June 24, 2025, where one post-consolidation share will be issued for every ten pre-consolidation shares. The consolidation aims to streamline the company’s share structure, with the post-consolidation shares trading under the existing symbol ‘RKV’ on the TSX Venture Exchange, potentially impacting the company’s market positioning and shareholder value.
More about Rakovina Therapeutics Inc
Rakovina Therapeutics is a biopharmaceutical research company focused on developing innovative cancer treatments using unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI). The company aims to advance drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Average Trading Volume: 421,358
Technical Sentiment Signal: Sell
Current Market Cap: C$11.61M
Find detailed analytics on RKV stock on TipRanks’ Stock Analysis page.